 | ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it... 3 KB (170 words) - 14:16, 24 August 2023 |
 | "Approval and initiation of the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine". News Powered by Cision. Retrieved 2021-04-29. "Alliance Members"... 19 KB (1,171 words) - 14:44, 10 April 2024 |
| Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021. "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects". ClinicalTrials... 98 KB (20,593 words) - 02:58, 8 March 2024 |
DelNS1-2019-nCoV-RBD-OPT GRAd-COV2 ImmunityBio iNCOVACC INNA-051 NDV-HXP-S Vaxart COVID-19 vaccine Virus-like particles ABNCoV2 LYB001 MigVax-101 VBI-2902... 181 KB (23,901 words) - 14:23, 6 January 2024 |